Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 7 of 56 for:    severe preeclampsia AND gestational
Previous Study | Return to List | Next Study

Early Placental Insufficiency Screening (BIODOP-T1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01348711
Recruitment Status : Completed
First Posted : May 5, 2011
Last Update Posted : May 5, 2011
Sponsor:
Collaborator:
Institut National de la Santé Et de la Recherche Médicale, France
Information provided by:
University Hospital, Tours

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
To assess the role of uterine artery and maternal serum PlGf and sflt-1 and their combination in screening for pre-eclampsia and small -for-gestational age (SGA) fetuses at 12-14 weeks of gestation

Condition or disease
Pre-eclampsia

Detailed Description:

Pre-eclampsia (PE) and intrauterine growth restriction (IUGR) are known as major factors in perinatal morbidity and mortality. Routine antenatal care is focused on the detection of women at increased risk to apply this population a program of careful monitoring and appropriate intervention.

Uterine artery Doppler during anomaly scan at 12 to 14 weeks in selected women at increased risk, has proved to be accurate to detect those who will develop PE or IUGR during the second half of pregnancy.

A variety of angiogenic proteins have been studied as potential markers for pre-eclampsia. Among these protein Plgf and sflt-1 have respectively demonstrated higher and lower levels in pregnant women who will subsequently develop pre-eclampsia.

Our study is aimed to evaluate the performance of serum Plgf and sflt-1 measurement in association with uterine artery Doppler as a screening for placental insufficiency.


Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Estimated Enrollment : 300 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Placental Insufficiency Screening During First Trimester by a Combination of Uterine Artery Dopppler, Maternal PlGF and sFLT-1 in Hight Risk Population
Study Start Date : May 2007
Actual Primary Completion Date : February 2011
Actual Study Completion Date : May 2011

Resource links provided by the National Library of Medicine


Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Occurrence for Pre-eclampsia or SGA [ Time Frame: During pregnancy and until 72h after delivery ]
    Pre-eclampsia is defined as hypertension (systolic blood pressure 140mmHg or greater or a diastolic blood pressure 90mmHg or greater on at least 2 occasions 4 hour or 1 week apart) accompanied by proteinuria (more or equal to 0.5g/day or 1 dipstick of ++ or more). SGA is defined as birth weight below the 10th centile for gestational age at birth according to the national birthweight distribution of the french population (INSERM)


Secondary Outcome Measures :
  1. Early onset pre-eclampsia [ Time Frame: During pregnancy and until 72h after delivery ]
    Early onset pre-eclampsia is defined as pre)eclampsia occurring before 32 completed gestational weeks.

  2. Severe pre-eclampsia [ Time Frame: During pregnancy and until 72h after delivery ]
    Severe pre-eclampsia is defined as systolic blood pressure of 160mmHg or greater or a diastolic blood pressure of 110mmHg or greater and/or proteinuria greater than 5g in 24 hour collection or occurrence of abruption, eclampsia (seizures during pre-eclampsia), HELLP syndrome (hemolysis, elevated enzyme liver, low platelets), renal insufficiency, fetal demise or birth weight below the 5th centile for gestational age.


Biospecimen Retention:   Samples Without DNA
SERUM

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Pregnant between 12 and 14 weeks
Criteria

Inclusion Criteria:

  • Chronic hypertension under medication
  • Insulin or not insulin dependant preexisting diabetes
  • Previous history of pre-eclampsia
  • Previous history of unexplained stillbirth
  • Previous history of placental abruption
  • Previous history of SGA (< 10th centile)
  • History of pre-eclampsia or chronic hypertension before 45 years in the mother or a sister
  • History of vascular pathology before 50 years in the father
  • Obesity (BMI>26)
  • Nulliparous after 38 years
  • Assisted conception with donor
  • Primipaternity after 38 years old or before 20 years old

Exclusion Criteria:

  • Multiple pregnancy
  • Pregnancy requiring termination
  • Unability to understand the study
  • Thrombophilia
  • treatment with heparin
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01348711


Locations
Layout table for location information
France
Hospital of Blois -Service de Gynécologie-Obstétrique
Blois, France, 41016
CHRU Hôpital Hôtel-Dieu Département Gynécologie Obstétrique
Nantes, France, 44093
Hôpital La Milétrie, CHRU Poitiers
Poitiers, France, 86021
Olympe de Gouges Women Health Centre, Bretonneau University Hospital
Tours, France, 37044
Sponsors and Collaborators
University Hospital, Tours
Institut National de la Santé Et de la Recherche Médicale, France
Investigators
Layout table for investigator information
Study Director: Franck PERROTIN, MD-PHD Univsersity Hospital of TOURS
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for additonal information
Responsible Party: University Hospital Tours, Direction de la Recherche
ClinicalTrials.gov Identifier: NCT01348711     History of Changes
Other Study ID Numbers: PHRI/06/FP-BIODOP-T1
First Posted: May 5, 2011    Key Record Dates
Last Update Posted: May 5, 2011
Last Verified: May 2011
Keywords provided by University Hospital, Tours:
Pre-eclampsia
Additional relevant MeSH terms:
Layout table for MeSH terms
Eclampsia
Pre-Eclampsia
Placental Insufficiency
 Hypertension, Pregnancy-Induced
Pregnancy Complications
Placenta Diseases